Compare Sana Biotechnology Inc (SANA) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.99 (market cap $2.03B). The key difference: Direxion Daily 20 Year Treasury Bull 3X Shares is far larger — about 2.4× Sana Biotechnology Inc's market cap, and Direxion Daily 20 Year Treasury Bull 3X Shares is more actively traded (12,241,664 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| SANA | TMF | |
|---|---|---|
Market Cap | $836.71M | $2.03B |
Volume | 4,507,444 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $5.92 | $44.14 |
52-Week Low | $2.68 | $25.19 |
Typical Hold Time | 23 Days | 28 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $25.93, up 2.75% with elevated volume. Technical indicators show a bearish trend from moving averages, though oscillators are neutral. The ETF saw increased trading interest recently, with support at $25 and resistance at $26.
As a leveraged ETF tracking long-term Treasuries, TMF's outlook hinges on interest rate trends. Opportunities exist if rates fall, but risks include rate hikes and volatility decay. Investors should monitor Fed policy for directional cues amid current bearish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
